Design and analysis of trials of salvage therapy in acute myelogenous leukemia

Cancer Chemotherapy and Pharmacology, Supplement

Volumn 40, Issue , 1997, Pages

  Estey, Elihu ^a,b   Thall, Peter ^a   David, Cynthia ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bayesian design; Leukemia; Phase I trials; Phase II trials; Relapsed refractory acute myelogenous; Stratification

Indexed keywords

CLADRIBINE; CYCLOSPORIN; CYTARABINE; DAUNORUBICIN; PACLITAXEL; SEBRIPLATIN; TOPOTECAN;

ACUTE GRANULOCYTIC LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; INFORMATION PROCESSING; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RELAPSE; SALVAGE THERAPY; STATISTICS;

EID: 0030788301     PISSN: 09439404     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800051054     Document Type: Conference Paper

References (8)

1. Estey E, Kornblau S, Pierce S, Kantarjian H, Beran M, Keating M (1996) A stratification system for evaluating and selecting therapies in patients with relapsed or refractory AML. Blood 88:756
2. Thall PF, Estey E (1993) A Bayesian strategy for screening cancer treatments prior to phase II evaluation. Stat Med 12:1197
3. Hiddemann W, Martin WR, Sauerland CM, Heinecke A, Buchner T (1990) Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy. Leukemia 4:184
4. Kornblau SM, Gandhi V, Andreeff M, Beran M, Kantarjian H, Koller CA, O'Brien S, Plunkett W, Estey E (1996) Clinical and laboratory studies of 2-chlorodeoxyadenosine ± cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia 10:1563
5. List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futscher V, Baier M, Dalton W (1993) Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 11:1652
6. Santana VM, Mirro J Jr, Kearns C, Schell MJ, Crom W, Blakely RL (1992) 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol 10:364
7. Simon R, Wittes RE, Ellenberg SS (1985) Randomized phase II clinical trials. Cancer Treat Rep 69:1375
8. Gehan E (1961) The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 13:346